N- and C-terminal truncation and deletion mutants of human interleukin-3
AssigneeGist-Brocades N.V.
InventorsLambertus C. J. Dorssers, Robert W. van Leen
Life of this patent
Estimating the term…
Abstract
Biologically active deletion and substitution mutants of hIL-3 are provided. Preferred mutants are those having one or more deletions at the N-terminus (amino acids 1-14) and/or the C-terminus (amino acids 116-133, 120-130 and/or 130-133). Preferred substitution mutants include Cys.sup.16 .fwdarw.Ala.sup.16 and/or Cys.sup.84 .fwdarw.Ala.sup.84, Glu.sup.50 .fwdarw.Lys.sup.50 and Lys.sup.79 .fwdarw.Glu.sup.79. These mutants can be used to formulate pharmaceutical compositions. Also disclosed are antibodies directed against specific epitopes localized between amino acids 29 and 54.
Claims4
A biologically active modified form of human interleukin-3 (IL-3), wherein the modification is selected from the group consisting of:
- deletion of amino acids 120-130 of human IL-3;
- deletion of amino acids 120-133 of human IL-3;
- deletion of amino acids 116-133 of human IL-3;
- and
- deletion of amino acids 130-133 of human IL-3.
A biologically active modified form of human interleukin-3 (IL-3), wherein the modification consists of deletion of at least two amino acids within the range of amino acids 1-14, in combination with
- deletion of amino acids 120-130 of human IL-3;
- deletion of amino acids 120-133 of human IL-3;
- deletion of amino acids 116-133 of human IL-3;
- or
- deletion of amino acids 130-133 of human IL-3.
Dependencies are inferred from the claim text.